Pharmacology & ToxicologybioRxivPreprint
ω-imidazolyl-alkyl derivatives as new preclinical drug candidates for NASH therapy
T. Diesinger, A. Lautwein, V. Buko…·T. Haehner
The paper tests two new CYP2E1 inhibitors, I-ol and I-an, in a rat model of NASH, finding they reduce pathological markers and show good tolerability.
DOI 10.1101/685115